Hypercholesterolemia and Dyslipidemia: Issues for the clinician

  • H. Robert Superko
  • Nicolas A. Chronos
Article

Opinion statement

The current state of the art in the diagnosis and treatment of lipoprotein disorders has progressed beyond the standard “lipid profile,” which includes total low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, along with fasting triglycerides. Incorporating aspects of the atherogenic lipoprotein profile (ALP) (ALP and LDL subclass distribution), HDL subclass distribution, apolipoprotein E isoforms, lipoprotein (a), homocysteine, and high-sensitivity C-reactive protein provides the clinician with the tools to create a more detailed, accurate, and personalized diagnosis of disorders contributing to coronary artery disease in their patients. Sophisticated laboratory tests are available to clinicians through technology transfer programs as exemplified by the Lawrence Berkeley National Laboratory/Berkeley HeartLab, Berkeley, CA, collaboration and allow clinicians access to research quality laboratory tools. This has significant clinical relevance because the presence of these disorders guides treatment that is specific to the disorder(s). Appropriate treatment has been shown to have significantly greater clinical benefit in patient subgroups exhibiting the disorder the therapy is most likely to correct. A single drug or lifestyle therapy plan is no longer appropriate for all patients. The treatment must match the individual disorder(s).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Superko HR: Inherited disorders in the lipoprotein system. A common cause of premature heart disease.In Women and Heart Disease. Edited by Julian DG, Wenger NK. London: Martin Dunitz; 1997:49–67.Google Scholar
  2. 2.
    Goldbourt U, de Faire U, Berg K: Genetic Factors in Coronary Heart Disease. Hingham, MA: Kluwer Academic Publishers; 1994.Google Scholar
  3. 3.
    Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448–454.PubMedCrossRefGoogle Scholar
  4. 4.
    Superko HR: What can we learn about dense LDL and lipoprotein particles from clinical trials? Curr Opin Lipidol 1996, 7:363–368.PubMedCrossRefGoogle Scholar
  5. 5.
    Margolis JR, Brown CL, Picardi K, Superko HR: Elevated LDL-IVb predicts multiple invasive cardiac procedures [abstract]. Circulation 2002, in press.Google Scholar
  6. 6.
    Manninen V, Elo O, Frick H, et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641–651.PubMedCrossRefGoogle Scholar
  7. 7.
    Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992, 85:37–45.PubMedGoogle Scholar
  8. 8.
    Superko HR: Beyond LDL-C reduction. Circulation 1996, 94:2351–2354.PubMedGoogle Scholar
  9. 9.
    Zambon A, Brown BG, Deeb SS, Brunzell JD: Hepatic lipase as a focal point for the development and treatment of coronary artery disease. J Invest Med 2001, 49:112–118. The link between hepatic lipase, small LDL, and arteriographic change in coronary arteries is a recent advance in the understanding of atherosclerosis. The current state of understanding is nicely explained in this article.Google Scholar
  10. 10.
    Deckelaum RJ, Olivecrona T, Eisenberg S: Plasma lipoproteins in hyperlipidemia: roles of neutral lipid exchange and lipase. In Treatment of Hyperlipoproteinemia.Edited by Carlson LA, Olsson AG. New York: Raven Press; 1984:85–93.Google Scholar
  11. 11.
    Grundy SM: Hyperlipoproteinemia: metabolic basis and rationale for therapy. Am J Cardiol 1984, 54:20C-26C.PubMedCrossRefGoogle Scholar
  12. 12.
    Miller NE: Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987, 113:589–597.PubMedCrossRefGoogle Scholar
  13. 13.
    Superko HR, Enas EA, Kotha P, et al.: Impaired reverse cholesterol transport in Asian Indians. J Am Coll Cardiol 2001, 37:300A.Google Scholar
  14. 14.
    Brown GB, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592. This recent arteriographic study reveals the importance of change in Lp(AI) and HDL2 in regard to coronary arteriographic change with combination lipid therapy.PubMedCrossRefGoogle Scholar
  15. 15.
    Krauss RM, Blanche PJ: Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992, 3:377–383.CrossRefGoogle Scholar
  16. 16.
    Gofman JW, Young W, Tandy R: Ischemic heart disease, atherosclerosis and longevity. Circulation 1966, 34:679–697.PubMedGoogle Scholar
  17. 17.
    Superko HR: Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998, 82:34–46.CrossRefGoogle Scholar
  18. 18.
    Superko HR: The atherogenic lipoprotein profile. Sci Med 1997, 4:36–45.Google Scholar
  19. 19.
    Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5:339–349.PubMedCrossRefGoogle Scholar
  20. 20.
    Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation 1997, 95:69–75.PubMedGoogle Scholar
  21. 21.
    Miller BD, Alderman EL, Haskell WL, et al.: Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention project. Circulation 1996, 94:2146–2153.PubMedGoogle Scholar
  22. 22.
    Watts GF, Mandalia S, Brunt JN, et al.: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas’ Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461–1467.PubMedCrossRefGoogle Scholar
  23. 23.
    Zambon A, Brown BG, Hokansen JE, Brunzell JD: Hepatic lipase changes predicts coronary artery disease regression/progression in the Familial Atherosclerosis Treatment Study. Circulation 1996, 94:I-539.Google Scholar
  24. 24.
    Superko HR, Krauss RM, Miller B: Prediction of LDL subclass pattern from Trig, HDLC, LDLC, apoB. Paper presented at the Cardiovascular Health. San Francisco, CA; February 19, 1998. 2Google Scholar
  25. 25.
    Superko HR, Schott RJ, Barr C, Raul E: Comparison of traditional and alternative laboratory methods for the determination of lipid measurements, Lp(a) and LDL phenotype [abstract]. Circulation 2002, 105:14. This investigation reports the comparison of two alternative laboratory methods for the determination of LDL subclass distribution, Lp(a), and LDL particle number with traditional laboratory methods.Google Scholar
  26. 26.
    Lindgren FT, Jensen LC, Hatach FT: The isolation and quantitative analysis of serum lipoproteins. In Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. Edited by Nelson GJ. New York: Wiley-Interscience; 1972:181–274.Google Scholar
  27. 27.
    Williams PT, Krauss RM, Vranizan KM, Wood PD: Changes in lipoprotein subfractions during dietinduced and exercise-induced weight loss in moderately overweight men. Circulation 1990, 81:1293–1304.PubMedGoogle Scholar
  28. 28.
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.Google Scholar
  29. 29.
    Brown MS, Goldstein JL: The LDL receptor concept: clinical and therapeutic implications. Atherosclerosis Rev 1988, 18:85.Google Scholar
  30. 30.
    Stone NJ, Levy RI, Fredrickson DS, Verter J: Coronary artery disease in 116 kindreds with familial type II hyperlipoproteinemia. Circulation 1974, 49:476–485.PubMedGoogle Scholar
  31. 31.
    Innerarity TL: Familial hypobetalipoproteinemia and familial defective apolipoprotein B100: genetic disorders associated with apolipoprotein B. Curr Opin Lipidol 1990, 1:104–109.CrossRefGoogle Scholar
  32. 32.
    Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539–540.PubMedCrossRefGoogle Scholar
  33. 33.
    Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007–3012.PubMedCrossRefGoogle Scholar
  34. 34.
    Williams D, Feely J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002, 41:343–370.PubMedCrossRefGoogle Scholar
  35. 35.
    Prueksaritanont T, Zhao JJ, Ma B, et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301:1042–1051. This report explains one possible mechanism for adverse interactions between gemfibrozil and statin medications.PubMedCrossRefGoogle Scholar
  36. 36.
    Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622–630.PubMedCrossRefGoogle Scholar
  37. 37.
    Gregg RE, Zech LA, Schaefer EJ, et al.: Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986, 78:815–821.PubMedGoogle Scholar
  38. 38.
    Superko HR: The effect of apolipoprotein E isoform difference on postprandial lipoprotein composition in patients matched for triglycerides, LDL-cholesterol and HDL-cholesterol. Artery 1991, 18:315–325.PubMedGoogle Scholar
  39. 39.
    Brown AJ, Roberts DCK: The effect of fasting triacylglyceride concentration and apolipoprotein E polymorphism on postprandial lipemia. Arterioscler Thromb Vasc Biol 1991, 11:1737–1744.Google Scholar
  40. 40.
    Mahley RW: Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am 1982, 66:375–400.PubMedGoogle Scholar
  41. 41.
    Corder EH, Saunders AM, Strittmatter WJ, et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261:921–923.PubMedCrossRefGoogle Scholar
  42. 42.
    Manttari M, Koskinen P, Ehnholm C, et al.: Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism 1991, 40:217–221.PubMedCrossRefGoogle Scholar
  43. 43.
    Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1–21.PubMedGoogle Scholar
  44. 44.
    Scanu A: Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA 1992, 267:3326–3329.PubMedCrossRefGoogle Scholar
  45. 45.
    Brown SA, Hutchinson R, Morrisett J, et al.: Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. Arterioscler Thromb Vasc Biol 1993, 13:1139–1158.Google Scholar
  46. 46.
    Terres W, Tatsis E, Pfalzer B, et al.: Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 1995, 91:948–950.PubMedGoogle Scholar
  47. 47.
    Sandkamp M, Funke H, Schelte H, et al.: Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990, 36:20–23.PubMedGoogle Scholar
  48. 48.
    Dahlen GH, Guyton JR, Attar M, et al.: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986, 74:758–765.PubMedGoogle Scholar
  49. 49.
    Budde T, Fechtrup C, Bosenberg E, et al.: Plasma lp(a) levels correlate with number, severity, and lengthextension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1994, 14:1730–1736.Google Scholar
  50. 50.
    Marquez A, Mendoza S, Carrasco H, et al.: High Lp(a) in children from kindreds with parental premature myocardial infarction. Pediatr Res 1993, 34:670–674.PubMedCrossRefGoogle Scholar
  51. 51.
    Schaefer EJ, Lamon-Fava S, Jenner JL, et al.: Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994, 271:999–1003.PubMedCrossRefGoogle Scholar
  52. 52.
    Daida H, Lee YJ, Yokoi H, et al.: Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994, 73:1037–1040.PubMedCrossRefGoogle Scholar
  53. 53.
    Maher VMG, Brown BG, Marcovina S, et al.: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771–1774.PubMedCrossRefGoogle Scholar
  54. 54.
    Shlipak MG, Simon JA, Vittinghoff E, et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000, 283:1845–1852. This report on the effect of HRT on Lp(a) values and clinical cardiovascular events raises the interesting issue of a subset of postmenopausal women with CAD who may benefit from HRT.PubMedCrossRefGoogle Scholar
  55. 55.
    Brewer HB Jr: Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In Lipoprotein (a). Edited by Scanu AM. New York, NY:Academic Press; 1990:211–220.Google Scholar
  56. 56.
    Gurakar A, Hoeg JM, Kostner G, et al.: Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985, 57:293–301.PubMedCrossRefGoogle Scholar
  57. 57.
    Kim CJ, Jang HC, Cho DH, Min YK: Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women. Arterioscler Thromb Vasc Biol 1994, 14:275–281.Google Scholar
  58. 58.
    Shewmon DA, Stock JL, Rosen CJ, et al.: Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 1994, 14:1586–1593.Google Scholar
  59. 59.
    Kostner GM, Gavish D, Leopold B, et al.: HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989, 80:1313–1319.PubMedGoogle Scholar
  60. 60.
    Goldstein JL, Schrott HG, Hazzard WR, et al.: Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973, 52:1544–1568.PubMedCrossRefGoogle Scholar
  61. 61.
    Sniderman A, Shapiro S, Marpole D, et al.: The association of coronary atherosclerosis and hyperapobetalipo-proteinemia (increased protein but normal cholesterol content in human plasma low density lipoprotein). Proc Natl Acad Sci U S A 1980, 97:604–608.CrossRefGoogle Scholar
  62. 62.
    Hunt SC, Wu LL, Hopkins PN, et al.: Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia (study of Utah patients with familial dyslipidemic hypertension). Arteriosclerosis 1989, 9:335–344.PubMedGoogle Scholar
  63. 63.
    Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.PubMedCrossRefGoogle Scholar
  64. 64.
    Kwiterovich PO: Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol 1993, 4:133–143.CrossRefGoogle Scholar
  65. 65.
    Knopp RH, Walden CE, Retzlaff BM, et al.: Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. JAMA 1997, 278:1509–1515.PubMedCrossRefGoogle Scholar
  66. 66.
    Brown BG, Zambon A, Poulin D, et al.: Use of niacin, statins, and resins in patients with combined hyperlipidemia. Am J Cardiol 1998, 81:52B-59B.PubMedCrossRefGoogle Scholar
  67. 67.
    Berge KG, Canner PL, Hainline A: High density lipoprotein cholesterol and prognosis after myocardial infarction. Circulation 1982, 66:1176–1181.PubMedGoogle Scholar
  68. 68.
    Goldbourt U, Cohen L, Neufeld HN: High density lipoprotein cholesterol: prognosis after myocardial infarction. Int J Epidemiol 1986, 15:51–55.PubMedCrossRefGoogle Scholar
  69. 69.
    Johansson J, Carlson LA, Landow C, Hamsten A: High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb Vasc Biol 1991, 11:174–182.Google Scholar
  70. 70.
    Vergani C, Beattale G: Familial hypo-alpha-lipoproteinemia. Clin Chim Acta 1981, 114:45–52.PubMedCrossRefGoogle Scholar
  71. 71.
    Genest J, Bard JM, Fruchart JC, et al.: Familial hypoalphalipoproteinemia in premature CAD. Arterioscler Thromb Vasc Biol 1993, 13:1728–1737.Google Scholar
  72. 72.
    Ordovas JM, Schaefer EJ, Salem D, et al.: Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med 1986, 314:671–677.PubMedCrossRefGoogle Scholar
  73. 73.
    King JM, Crouse JR, Terry JG, et al.: Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med 1994, 97:323–331.PubMedCrossRefGoogle Scholar
  74. 74.
    Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO: Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Am J Med 1993, 94:7–20.PubMedCrossRefGoogle Scholar
  75. 75.
    Selhub J, Jacques PF, Bostom AG, et al.: Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995, 332:286–291.PubMedCrossRefGoogle Scholar
  76. 76.
    Malinow MR, Nieto J, Szklo M, et al.: Carotid artery intimalmedial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993, 87:1107–1114.PubMedGoogle Scholar
  77. 77.
    Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775–1781.PubMedCrossRefGoogle Scholar
  78. 78.
    Schnyder G, Roffi M, Flammer Y, et al.: Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002, 23:726–733. The link between elevated plasma homocysteine levels and restenosis is reported in this article.PubMedCrossRefGoogle Scholar
  79. 79.
    Zhao XQ, Kosinski AJS, Malinow MR, et al.: Association of total plasma homocysteine levels and 8-year mortality following PTCA or CABG in EAST. Circulation 2000, 102:II-699.Google Scholar
  80. 80.
    Schnyder G, Roffi M, Flammer Y, et al.: Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. JAMA 2002, 288:973–979. This is the first study to report a reduction in clinical outcomes following PCI and treatment for elevated homocysteine levels.PubMedCrossRefGoogle Scholar
  81. 81.
    Blankenhorn DH, Malinow MR, Mack WJ: Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Artery Dis 1991, 2:357–360.CrossRefGoogle Scholar
  82. 82.
    Stulc T, Melenovsky V, Grauova B, et al.: Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition 2001, 17:721–723. This paper reveals an increase in plasma homocysteine levels associated with fenofibrate treatment.PubMedCrossRefGoogle Scholar
  83. 83.
    Schwaninger M, Ringleb P, Winter R, et al.: Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999, 40:345–350.PubMedCrossRefGoogle Scholar
  84. 84.
    Liuzzo G, Biasucci LM, Rebuzzi AG, et al.: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996, 94:2373–2380.PubMedGoogle Scholar
  85. 85.
    Ridker PM, Hennekens CH, Buring JE, Rifai B: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843. This reports on the importance of elevated hs-CRP in CAD risk prediction in women and reveals an interaction with other cardiovascular risk factors.PubMedCrossRefGoogle Scholar
  86. 86.
    Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007–2011.PubMedGoogle Scholar
  87. 87.
    Toss H, Lindahl B, Siegbahn A, Wallentin L: Prognostic influence of increased fibrinogen and C-reactive aprotein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997, 98:4204–4210.Google Scholar
  88. 88.
    Ferreiros ER, Boissonnet CP, Pizarro R, et al.: Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999, 100:1958–1963.PubMedGoogle Scholar
  89. 89.
    Milazzo D, Biasucci LM, Luciani N, et al.: Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999, 84:459–461.PubMedCrossRefGoogle Scholar
  90. 90.
    Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • H. Robert Superko
    • 1
  • Nicolas A. Chronos
    • 1
  1. 1.American Cardiovascular Research InstituteAtlantaUSA

Personalised recommendations